Table 1.

Baseline characteristics of patients with tuberculosis .

Patient	Age, Years	Sex	Malignancy	Prior lines of treatment	Conditioning regimen	CAR T-cell dose	In tandem with ASCT	CRS grade	CRS treatment	Time-to neutrophil recovery†	Time-to endogenous B-cell recovery†
1	45	Male	MCL	7	BEAM	CAR19 T cells 3×106/kg; CAR22 T cells 3×106/kg	Yes	2	Dexamethasone 10 mg per day for 3 days	14 days	3 months
2	29	Female	ALL	3	FC	CAR19 T cells 4×106/kg; CAR22 T cells 4×106/kg	No	1	Supportive	7 days	3 months
3	60	Male	DLBCL	4	BEAM	CAR19 T cells 4.5×106/kg; CAR22 T cells 5.6×106/kg	Yes	1	Supportive	20 days	10 months
4	23	Male	DLBCL	3	BEAM	CAR19 T cells 4.6×106/kg; CAR22 T cells 4.1×106/kg	Yes	1	Supportive	9 days	13 months
5	63	Female	FL	3	FC	CAR19 T cells 2×106/kg; CAR22 T cells 2.7×106/kg	No	1	Supportive	10 days	N/A*

^†Time calculated since CAR T-cell infusion. ^* B cells remained significantly depleted at the last follow-up at 12 months post CAR T-cell therapy.

MCL: mantle cell lymphoma; ALL: acute lymphocytic leukemia; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; BEAM: bis-carmusitine, etoposide, cytarabine and melphalan; FC: fludarabine and cyclophosphamide; CAR: chimeric antigen receptor; CAR19: CD19-targeted chimeric antigen receptor; CAR22: CD22-targeted chimeric antigen receptor; ASCT: autologous stem cell transplantation; CRS: cytokine release syndrome; N/A: not applicable